Some targeted therapy drugs that are directed at (target) proteins to prevent, treat and reduce the risk of breast cancer recurrence are monoclonal antibody like Trastuzumab (Herceptin). Trastuzumab is an antibody drug that specially target HER2-positive cancer cells. Trastuzumab attaches to the HER2 protein on the surface of HER2-positive breast cancer cells and slow/stop their growth.
1989
Isolation of a monoclonal antibody named with high specificity towards HER
1998
Trastuzumab approved in US for treatment of HER2 positive breast cancer
2000
Trastuzumab approved in Europe
2006
Trastuzumab approved for treatment in adjuvant of HER2 node positive breast cancer
2007
Lapatinib approved for HER2 breast cancer
2013
Trastuzumab emtansine was approved in USA breast cancer
2014
Trastuzumab biosimilar Hertraz (MYL-14010) was approved in India and the trastuzumab biosimilar CT-P6 was approved in Korea
2017
Trastuzumab was added to the South African Essential Medicines List (EML) in 2017 for the adjuvant management of HER2-positive early breast cancer.
2019
Biosimilar agents currently approved in the European Union, the United States, and Canada Enoxaparin sodium (2017), Bevacizumab & Adalimumab (2017), Herzuma (2018), Ontruzant/ Trazimera/ Kanjinti (2019)
2020
FDA approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin)
2022
Enhertu approved in USA
Top patented combination of trastuzumab
Oxaliplatin
Capecitabine
Pertuzumab
Neratinib
Vinflunine
Vinblastine
Lapatinib
Tucatinib
Biosimilar of Trastuzumab
- Zercepac®, Adalimumab and bevacizumab (China)
- UJVIRA, HertrazTM (India)
- Trazimera (USA)
- SB3 (Ontruzant®), Herzuma (Europe)
Trastuzumab Deruxtecan trials have introduced a new subtype of HER2 expressing metastatic breast cancer. Targeting and treating HER2-low breast cancer HER 2 low breast cancer, which represent at least 50% of breast cancer have raised new challenges. Unfortunately, the low HER2 expression failed to provide clinical prognosis benefits. The available HER2-targeted therapies are inefficient in HER2-low BC, and treatment options are restricted after the initial treatment progression. Despite the ineffectiveness of trastuzumab for HER2-low BC, the ability of ADCs to significantly improve prognosis has spurred interest in conventional targeted agents
